Latest from USC Norris

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the potential for immunotherapy in metastatic colorectal cancer.
Michael Pulsipher, MD, director of cellular therapy and stem cell transplantation, professor of pediatrics, USC Keck School of Medicine, discusses the role of MRD testing in pediatric patients treated with CAR T-cell therapy.
Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses the impact of peptide receptor radionuclide therapy (PRRT) on the treatment of patients with neuroendocrine tumors (NETs).
Afsaneh Barzi, MD, assistant professor of clinical medicine, Norris Comprehensive Cancer Center, University of Southern California, discusses available and emerging neoadjuvant strategies for the treatment of patients with nonmetastatic pancreatic cancer.
Syma Iqbal, MD, discusses the evolving treatment paradigm of neuroendocrine tumors.
The second-line treatment of gastric and gastroesophageal junction cancers has shifted considerably in the last few years, due in part to the addition of immunotherapy for select subgroups of patients.
 
Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the benefit of regorafenib (Stivarga) in the treatment of patients with colorectal cancer (CRC).
Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses second- and third-line therapies in gastric cancer.
Publication Bottom Border
Border Publication
x